NCT04695977

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

TERMINATEDPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2021-02-24Est. Completion: 2024-07-22

Enrollment target: 20 participants

Locations

Mayo Clinic Arizona, Phoenix, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Moores Cancer Center at UC San Diego Health, La Jolla, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States
Hartford Healthcare, Hartford, Connecticut, United States
Cleveland Clinic, Weston, Florida, United States
University Cancer & Blood Center, Athens, Georgia, United States
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
University of Louisville Health Care, Louisville, Kentucky, United States
Atlantic Health, Morristown, New Jersey, United States
Duke University Cancer Institute, Durham, North Carolina, United States
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

Acral Lentiginous MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Mucosal Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high…

Birmingham, United StatesEst. completion Sep 1, 2022

Radiation RetinopathyVisual Impairment

This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intr…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.